Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719948 | 0.98 | CASP3 (0.41) | CASP3SENP8SENP7SENP6MAPT | |
| SCHEMBL720636 | 0.95 | CASP3 (0.44) | CASP3SENP8SENP7SENP6MAPT | |
| SCHEMBL719193 | 0.89 | CASP3 (0.41) | CASP3SENP8SENP7SENP6MAPT | |
| SCHEMBL720091 | 0.89 | GABRA1 (0.39) | CASP3SENP8SENP7SENP6MAPT | |
| SCHEMBL719561 | 0.88 | MAPT (0.41) | CASP3SENP8SENP7SENP6MAPT | |
| SCHEMBL2669958 | 0.88 | CASP3 (0.39) | CASP3SENP8SENP7SENP6L3MBTL1 | |
| SCHEMBL721739 | 0.87 | NPC1 (0.40) | MAPTL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL717066 | 0.87 | CASP3 (0.45) | CASP3SENP8SENP7SENP6MAPT | |
| SCHEMBL719087 | 0.86 | CASP3 (0.40) | CASP3SENP8SENP7SENP6MAPT | |
| SCHEMBL718137 | 0.86 | KDM4E (0.36) | MAPTL3MBTL1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | CASP3 489/4885SENP8 1677/4885SENP7 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.